QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-eli-lilly-raises-price-target-to-1171

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1090...

 citigroup-maintains-buy-on-eli-lilly-raises-price-target-to-1500

Citigroup analyst Peter Verdult maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1250 to $1500.

 dow-jones-hits-record-highs-amd-jumps-whats-moving-markets-wednesday

Blue-chip stocks hit record highs as investors rotate toward old-economy leaders; AMD surges, gold rallies, oil slides on OPEC ...

Core News & Articles

- Reuters Citing UBS Healthcare Conf

 eli-lilly-drops-cvs-healths-drug-benefit-plan-for-employees-ahead-of-2026-switch

Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India t...

 eli-lilly-ceo-slams-pbm-rent-taking-says-they-drove-insulin-list-prices-to-275-we-can-disintermediate-them-easily

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready ...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-11-12/lilly-drops-cvs-drug-plan-for-workers-after-novo-obesity-deal 

 these-20-stocks-now-make-up-half-of-the-sp-500heres-why-thats-risky

A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, drive...

 trifecta-health-partners-with-eli-lillys-lillydirect-to-expand-affordable-access-to-zepbound-obesity-treatment

Trifecta Health and Trifecta Med Spa are excited to announce two strategic cooperations aimed at improving patient access to hi...

 freedom-capital-markets-downgrades-eli-lilly-to-hold-raises-price-target-to-950

Freedom Capital Markets analyst Ilya Zubkov downgrades Eli Lilly (NYSE:LLY) from Buy to Hold and raises the price target fro...

 eli-lilly-stock-surges-as-analyst-sees-more-room-to-run

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104.

 markets-cheer-as-shutdown-end-nears-these-15-stocks-are-rallying

Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown i...

 eli-lilly-expands-genetic-eye-disease-focused-pipeline-with-meiragtx-gene-therapy-collaboration

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children w...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION